Abstract CT289: Pembrolizumab plus lenvatinib vs docetaxel in patients with previously treated metastatic non small cell lung cancer (NSCLC) and PD after platinum doublet …

user-5ebe282a4c775eda72abcdce(2020)

Cited 0|Views4
No score
Abstract
Background: Pembrolizumab is approved for patients with metastatic NSCLC and PD-L1 tumor proportion score (TPS) ≥1%. The multireceptor tyrosine kinase inhibitor lenvatinib enhances antitumor activity of PD-1 inhibitors in vitro and has shown clinical activity with pembrolizumab in patients with metastatic NSCLC (NCT02501096). LEAP-008 (NCT03976375) evaluates the efficacy and safety of second/subsequent-line pembrolizumab plus lenvatinib vs docetaxel in patients with previously treated metastatic NSCLC refractory to anti-PD-(L)1 therapy and platinum-doublet chemotherapy. Methods: In this randomized, global, open-label, active-controlled study, patients (n = 405) with metastatic NSCLC who progressed after platinum-doublet chemotherapy and anti-PD-(L)1 therapy are randomized 4:4:1 to pembrolizumab 200 mg Q3W plus lenvatinib 20 mg once daily (Arm 1, n = 180), docetaxel 75 mg/m2 Q3W (Arm …
More
Translated text
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined